Skip to main content
SpringerLink
Log in

Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The HER2 gene is overexpressed in 15–20 % of all breast cancers. With the advent of HER2-directed therapies, HER2 overexpression is no longer considered an adverse prognostic factor. Despite significant improvements in clinical outcomes with the use of trastuzumab [herceptin (H)], women aged >65 years remain under-represented in most clinical trials. Cardiac safety in the elderly woman is a major concern because of pre-existing comorbidities. However, many studies suggest that elderly patients with HER2-positive disease derive the same benefit from trastuzumab as do their younger counterparts in both adjuvant and metastatic settings. Data are limited guiding safety and efficacy of other HER2 inhibitors such as pertuzumab and trastuzumab emtansine in elderly patients; however, in general, these drugs have a favorable toxicity profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010;28(9):963–8. doi:10.3109/07357907.2010.496759.

    Article  PubMed  Google Scholar 

  2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.

    Article  CAS  PubMed  Google Scholar 

  3. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 1992;10(7):1049–56.

    CAS  Google Scholar 

  4. Howlader N, Chen VW, Ries LA, Loch MM, Lee R, DeSantis C, et al. Overview of breast cancer collaborative stage data items—their definitions, quality, usage, and clinical implications: a review of SEER data for 2004–2010. Cancer. 2014;120(Suppl 23):3771–80. doi:10.1002/cncr.29059.

    Article  PubMed  Google Scholar 

  5. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. doi:10.1093/jnci/dju055.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, et al. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. Oncologist. 2014;19(10):1076–83. doi:10.1634/theoncologist.2014-0184.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(34):5700–6. doi:10.1200/JCO.2009.23.2025.

    Article  Google Scholar 

  8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.

    Article  CAS  PubMed  Google Scholar 

  9. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382(9897):1021–8. doi:10.1016/S0140-6736(13)61094-6.

    Article  CAS  PubMed  Google Scholar 

  10. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236–44. doi:10.1016/S1470-2045(11)70033-X.

    Article  CAS  PubMed  Google Scholar 

  11. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl J Med. 2005;353(16):1659–72. doi:10.1056/NEJMoa052306.

    Article  CAS  PubMed  Google Scholar 

  12. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(33):3744–52. doi:10.1200/JCO.2014.55.5730.

    Article  CAS  Google Scholar 

  13. Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14(8):741–8. doi:10.1016/S1470-2045(13)70225-0.

    Article  CAS  PubMed  Google Scholar 

  14. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. New Engl J Med. 2011;365(14):1273–83. doi:10.1056/NEJMoa0910383.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(34):5685–92. doi:10.1200/JCO.2008.21.4577.

    Article  CAS  Google Scholar 

  16. Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev. 2013;39(1):44–50. doi:10.1016/j.ctrv.2012.03.009.

    Article  CAS  PubMed  Google Scholar 

  17. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. New Engl J Med. 2015;372(2):134–41. doi:10.1056/NEJMoa1406281.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 2001;28(1 Suppl 3):13–9.

    Article  CAS  PubMed  Google Scholar 

  19. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(7):1800–8.

    Article  CAS  PubMed  Google Scholar 

  20. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–74.

    Article  CAS  PubMed  Google Scholar 

  21. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003;21(15):2889–95. doi:10.1200/JCO.2003.02.018.

    Article  CAS  PubMed  Google Scholar 

  22. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med. 2001;344(11):783–92. doi:10.1056/NEJM200103153441101.

    Article  CAS  PubMed  Google Scholar 

  23. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(5):1215–21.

    Article  CAS  Google Scholar 

  24. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985;55(12):2761–5.

    Article  CAS  PubMed  Google Scholar 

  25. Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99(6):745–9.

    Article  CAS  PubMed  Google Scholar 

  26. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol. 1992;19(5):529–42.

    CAS  PubMed  Google Scholar 

  27. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. New Engl J Med. 2004;351(2):145–53. doi:10.1056/NEJMoa035153.

    Article  CAS  PubMed  Google Scholar 

  28. Ewer MS, O’Shaughnessy JA. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer. 2007;7(8):600–7.

    Article  CAS  PubMed  Google Scholar 

  29. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(31):7820–6. doi:10.1200/JCO.2005.13.300.

    Article  CAS  Google Scholar 

  30. Klein PM, Dybdal N. Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol. 2003;30(5 Suppl 16):49–53.

    Article  CAS  PubMed  Google Scholar 

  31. Belmonte F, Das S, Sysa-Shah P, Sivakumaran V, Stanley B, Guo X, et al. ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015;309:H1271–80.

    Article  PubMed  Google Scholar 

  32. de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(20):2159–65. doi:10.1200/JCO.2013.53.9288.

    Article  Google Scholar 

  33. Perez EA. Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer. 2008;8(Suppl 3):S114–20.

    Article  CAS  PubMed  Google Scholar 

  34. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(25):3859–65. doi:10.1200/JCO.2006.09.1611.

    Article  CAS  Google Scholar 

  35. Tripathy D. Cardiac side effects of trastuzumab: lessons learned from targeting cancer pathways. Nat Clin Pract Oncol. 2007;4(4):220–1. doi:10.1038/ncponc0768.

    Article  CAS  PubMed  Google Scholar 

  36. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(3):719–26.

    Article  CAS  Google Scholar 

  37. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med. 2005;353(16):1673–84. doi:10.1056/NEJMoa052122.

    Article  CAS  PubMed  Google Scholar 

  38. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(31):3792–9. doi:10.1200/JCO.2011.40.0010.

    Article  CAS  Google Scholar 

  39. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of HER2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153. doi:10.1186/1471-2407-7-153.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(31):7811–9. doi:10.1200/JCO.2005.02.4091.

    Article  CAS  Google Scholar 

  41. Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(33):4222–8. doi:10.1200/JCO.2013.48.7884.

    Article  CAS  Google Scholar 

  42. Bonifazi M, Franchi M, Rossi M, Moja L, Zambelli A, Zambon A, et al. Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study. Oncologist. 2013;18(7):795–801. doi:10.1634/theoncologist.2013-0065.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Adamo V, Ricciardi GR, Adamo B, Ferraro G, Franchina T, Rossello R, et al. The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. Oncology. 2014;86(1):16–21. doi:10.1159/000353450.

    Article  CAS  PubMed  Google Scholar 

  44. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(25):4107–15. doi:10.1200/JCO.2005.04.9551.

    Article  CAS  Google Scholar 

  45. Yu AF, Yadav NU, Eaton AA, Lung BY, Thaler HT, Liu JE, et al. Continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction. Oncologist. 2015;. doi:10.1634/theoncologist.2015-0125.

    Google Scholar 

  46. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317–28.

    Article  CAS  PubMed  Google Scholar 

  47. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(7):1138–44. doi:10.1200/JCO.2009.24.2024.

    Article  CAS  Google Scholar 

  48. Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer. 2010;10(6):489–91. doi:10.3816/CBC.2010.n.065.

    Article  PubMed  Google Scholar 

  49. Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, et al. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat. 2013;142(1):89–99. doi:10.1007/s10549-013-2710-z.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2012;23(3):791–800. doi:10.1093/annonc/mdr294.

    Article  CAS  Google Scholar 

  51. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2013;24(9):2278–84. doi:10.1093/annonc/mdt182.

    Article  CAS  Google Scholar 

  52. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New Engl J Med. 2012;367(19):1783–91. doi:10.1056/NEJMoa1209124.

    Article  CAS  PubMed  Google Scholar 

  53. Krop IE, Kim SB, Gonzalez-Martin A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689–99. doi:10.1016/S1470-2045(14)70178-0.

    Article  CAS  PubMed  Google Scholar 

  54. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med. 2006;355(26):2733–43. doi:10.1056/NEJMoa064320.

    Article  CAS  PubMed  Google Scholar 

  55. Cetin B, Benekli M, Dane F, Boruban C, Gumus M, Oksuzoglu B, et al. Lapatinib plus capecitabine for HER2-positive advanced-stage breast cancer in elderly women: review of the Anatolian Society of Medical Oncology (ASMO) experience. Breast Care. 2013;8(1):67–70. doi:10.1159/000346829.

    Article  PubMed Central  PubMed  Google Scholar 

  56. de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15(10):1137–46. doi:10.1016/S1470-2045(14)70320-1.

    Article  PubMed  Google Scholar 

  57. Piccart-Gebhart MJ, Holmes AP, Baselga J, De Azambuja E, Dueck AC, Viale G, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T->L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). ASCO Meet Abstr. 2014;32:LBA4.

    Google Scholar 

  58. Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;118(1):84–95. doi:10.1161/CIRCULATIONAHA.108.776831.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Hasinoff BB, Patel D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol Appl Pharmacol. 2010;249(2):132–9. doi:10.1016/j.taap.2010.08.026.

    Article  CAS  PubMed  Google Scholar 

  60. Sendur MA, Aksoy S, Altundag K. Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin. 2013;29(8):1015–24. doi:10.1185/03007995.2013.807232.

    Article  CAS  PubMed  Google Scholar 

  61. Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2011;125(2):447–55. doi:10.1007/s10549-010-1260-x.

    Article  CAS  PubMed  Google Scholar 

  62. Andre F, Campone M, O’Regan R, Manlius C, Massacesi C, Sahmoud T, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(34):5110–5. doi:10.1200/JCO.2009.27.8549.

    Article  CAS  Google Scholar 

  63. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(23):3126–32. doi:10.1200/JCO.2010.32.2321.

    Article  CAS  Google Scholar 

  64. Andre F, O’Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580–91. doi:10.1016/S1470-2045(14)70138-X.

    Article  CAS  PubMed  Google Scholar 

  65. Pritchard KI, Burris HA 3rd, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clinical breast cancer. 2013;13(6):421–32 e8. doi:10.1016/j.clbc.2013.08.011.

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

    Jasmeet Chadha Singh & Stuart M. Lichtman

Authors
  1. Jasmeet Chadha Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stuart M. Lichtman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart M. Lichtman.

Ethics declarations

Conflict of interest

Stuart M. Lichtman and Jasmeet Chadha Singh declare no conflict of interest.

Funding

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, J.C., Lichtman, S.M. Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. Drugs Aging 32, 975–982 (2015). https://doi.org/10.1007/s40266-015-0326-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-015-0326-1

Keywords

Search

Navigation